Breaking News: Sinaptica’s Noninvasive Neuromodulation Device Slows Alzheimer’s Disease in Year-Long Trial
Hear the latest groundbreaking news in Alzheimer’s research. Sinaptica, a member of StartUp Health’s Alzheimer’s Moonshot Community, has announced significant results from its Phase 2 clinical trial testing the company’s noninvasive, personalized, precise neuromodulation designed to stop the progression of Alzheimer’s disease.
Ken Mariash, CEO of Sinaptica, joined us in the StartUp Health Studio to break it all down for us. As you’ll hear, the interview took place prior to the release of this data, which became public on October 31.
In this exclusive interview, you’ll learn:
- Details on Sinaptica’s Phase 2 trial results show significant promise in slowing Alzheimer’s progression
- The science behind Sinaptica’s technology
- How personalized neuromodulation is revolutionizing brain health
- The potential for proactive brain strengthening and repair
- The impact on patients’ daily lives
- The future of Alzheimer’s treatment
This episode is a must-listen for anyone interested in Alzheimer’s research, neuroscience, and the power of innovation to transform lives.
Are you ready to tell your story? Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world’s biggest health challenges. Exposure in StartUp Health Media to our global audience of investors and partners – including our podcast, newsletters, magazine, and YouTube channel – is a benefit of StartUp Health’s PRO Membership. To schedule a call and see if you qualify to join and increase brand awareness through our multi-media storytelling efforts, submit our three-minute application. If you’re mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit. Learn more and apply today.
Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.
